MLICM
ATXS

Metropolitan Life Insurance Company (MetLife)’s Astria Therapeutics ATXS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,641
Closed -$37.2K – 206
2024
Q1 		$37.2K Buy
2,641
+655
+33% +$8.16K ﹤0.01% 1554
2023
Q4 		$15.3K Buy
1,986
+580
+41% +$3.21K ﹤0.01% 2030
2023
Q3 		$10.5K Hold
1,406
– – ﹤0.01% 2183
2023
Q2 		$11.7K Buy
+1,406
New +$16.2K ﹤0.01% 2223

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ATXS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 2,641 shares — an estimated $37.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ATXS in Q2 2023 and held it in 4 quarters. The position peaked at $37.2K in Q1 2024. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,641 Astria Therapeutics shares in Q2 2024, an estimated $37.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Astria Therapeutics in Q2 2023 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Astria Therapeutics position peaked at $37.2K in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.